In February 2026, Novo Nordisk filed a federal patent infringement suit against Hims & Hers Health, one of the largest telehealth distributors of compounded semaglutide, in the U.S
ePA doesnt directly solve coverage denials, but by making the process transparent and trackable, it at least ensures that if a patient is denied, the rationale is clearly documented and can be appealed
Symptoms, physical examination, family history, cardiovascular-risk calculations, electrocardiography, imaging, and other evaluations may still be needed
They also may contain unlisted or dangerous ingredients, such as solvents, heavy metals, glass, plastic, fibers, bacteria, fungi or endotoxins